Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ilboudo, Adeodat ^a,c,d   Nault, Jean Charles ^b,e   Dubois Pot Schneider, Hélène ^b,c,d   Corlu, Anne ^b,c,d   Zucman Rossi, Jessica ^b,e   Samson, Michel ^a,c,d   Le Seyec, Jacques ^a,c,d  

^a UNIVERSITÉ DE RENNES 1   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

^d Fédération de Recherche BioSit de Rennes   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Biomarker; Hepatocellular carcinoma; PI4KA; Prognosis

Indexed keywords

MESSENGER RNA; PHOSPHATIDYLINOSITOL KINASE; PROTEIN PI4KA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); DISEASE SPECIFIC SURVIVAL; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER CELL CULTURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RECURRENCE; UNDIFFERENTIATED CARCINOMA; UPREGULATION;

CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84891528345     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-7     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
2. El-Serag HB. Hepatocellular carcinoma. The New England journal of medicine 2011, 365(12):1118-1127. 10.1056/NEJMra1001683, 21992124.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379(9822):1245-1255. 10.1016/S0140-6736(11)61347-0, 22353262.
4. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular Benign Tumors-From Molecular Classification to Personalized Clinical Care. Gastroenterology 2013, 144(5):888-902. 10.1053/j.gastro.2013.02.032, 23485860.
5. Bioulac-Sage P, Rebouissou S, Thomas C, Blanc JF, Saric J, Sa Cunha A, Rullier A, Cubel G, Couchy G, Imbeaud S, et al. Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology 2007, 46(3):740-748. 10.1002/hep.21743, 17663417.
6. Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, Leteurtre E, Paradis V, Michalak S, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43(3):515-524. 10.1002/hep.21068, 16496320.
7. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010, 30(1):35-51. 10.1055/s-0030-1247131, 3668687, 20175032.
8. Boyault S, Rickman DS, De Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007, 45(1):42-52. 10.1002/hep.21467, 17187432.
9. Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci U S A 2009, 106(18):7577-7582. 10.1073/pnas.0902693106, 2678598, 19376974.
10. Borawski J, Troke P, Puyang X, Gibaja V, Zhao S, Mickanin C, Leighton-Davies J, Wilson CJ, Myer V, Cornellataracido I, et al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J Virol 2009, 83(19):10058-10074. 10.1128/JVI.02418-08, 2748049, 19605471.
11. Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009, 5(3):298-307. 10.1016/j.chom.2009.02.001, 2756022, 19286138.
12. Trotard M, Lepere-Douard C, Regeard M, Piquet-Pellorce C, Lavillette D, Cosset FL, Gripon P, Le Seyec J. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. Faseb J 2009, 23(11):3780-3789. 10.1096/fj.09-131920, 19608626.
13. Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 2009, 387(1):5-10. 10.1016/j.virol.2009.02.039, 19304308.
14. Minogue S, Waugh MG. The Phosphatidylinositol 4-Kinases: Don't Call it a Comeback. Subcell Biochem 2012, 58:1-24. 10.1007/978-94-007-3012-0_1, 22403072.
15. Blumental-Perry A, Haney CJ, Weixel KM, Watkins SC, Weisz OA, Aridor M. Phosphatidylinositol 4-phosphate formation at ER exit sites regulates ER export. Dev Cell 2006, 11(5):671-682. 10.1016/j.devcel.2006.09.001, 17084359.
16. Farhan H, Weiss M, Tani K, Kaufman RJ, Hauri HP. Adaptation of endoplasmic reticulum exit sites to acute and chronic increases in cargo load. Embo J 2008, 27(15):2043-2054. 10.1038/emboj.2008.136, 2516884, 18650939.
17. Balla A, Kim YJ, Varnai P, Szentpetery Z, Knight Z, Shokat KM, Balla T. Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIalpha. Mol Biol Cell 2008, 19(2):711-721. 2230591, 18077555.
18. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006, 443(7112):651-657. 10.1038/nature05185, 17035995.
19. Waugh MG. Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer. Cancer Lett 2012, 325(2):125-131. 10.1016/j.canlet.2012.06.009, 22750097.
20. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, et al. A Hepatocellular Carcinoma 5-Gene Score Associated with Survival of Patients Following Liver Resection. Gastroenterology 2013, 145(1):176-187. 10.1053/j.gastro.2013.03.051, 23567350.
21. Laurent-Puig P, Legoix P, Bluteau O, Belghiti J, Franco D, Binot F, Monges G, Thomas G, Bioulac-Sage P, Zucman-Rossi J. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001, 120(7):1763-1773. 10.1053/gast.2001.24798, 11375957.
22. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002, 99(24):15655-15660. 10.1073/pnas.232137699, 137772, 12432097.
23. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005, 102(26):9294-9299. 10.1073/pnas.0503596102, 1166622, 15939869.
24. Rebouissou S, Imbeaud S, Balabaud C, Boulanger V, Bertrand-Michel J, Terce F, Auffray C, Bioulac-Sage P, Zucman-Rossi J. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation. J Biol Chem 2007, 282(19):14437-14446. 10.1074/jbc.M610725200, 17379603.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23(36):9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
26. Odom DT, Zizlsperger N, Gordon DB, Bell GW, Rinaldi NJ, Murray HL, Volkert TL, Schreiber J, Rolfe PA, Gifford DK, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004, 303(5662):1378-1381. 10.1126/science.1089769, 3012624, 14988562.
27. Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011, 9(1):32-45. 10.1016/j.chom.2010.12.002, 3433060, 21238945.
28. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012, 44(6):694-698. 10.1038/ng.2256, 3819251, 22561517.
29. Sainz B, Chisari FV. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol 2006, 80(20):10253-10257. 10.1128/JVI.01059-06, 1617281, 17005703.
30. Parent R, Marion MJ, Furio L, Trepo C, Petit MA. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology 2004, 126(4):1147-1156. 10.1053/j.gastro.2004.01.002, 15057753.
31. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, Roskams T, Durnez A, Demetris AJ, Thorgeirsson SS. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004, 40(3):667-676. 10.1002/hep.20375, 15349906.
32. Li J, Lu Y, Zhang J, Kang H, Qin Z, Chen C. PI4KIIalpha is a novel regulator of tumor growth by its action on angiogenesis and HIF-1alpha regulation. Oncogene 2010, 29(17):2550-2559. 10.1038/onc.2010.14, 20154717.
33. Ishikawa S, Egami H, Kurizaki T, Akagi J, Tamori Y, Yoshida N, Tan X, Hayashi N, Ogawa M. Identification of genes related to invasion and metastasis in pancreatic cancer by cDNA representational difference analysis. J Exp Clin Cancer Res 2003, 22(2):299-306.